Incyte Stock Price, News & Analysis (NASDAQ:INCY)

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 10 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings or view top-rated stocks.

19 analysts have issued 12-month target prices for Incyte's shares. Their INCY share price targets range from $61.00 to $100.00. On average, they expect the company's share price to reach $79.94 in the next twelve months. This suggests a possible upside of 51.7% from the stock's current price.
View analysts price targets for INCY or view top-rated stocks among Wall Street analysts.

Incyte's stock was trading at $80.32 at the beginning of the year. Since then, INCY stock has decreased by 34.4% and is now trading at $52.70.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024.
View our INCY earnings forecast.

Incyte Co. (NASDAQ:INCY) released its quarterly earnings data on Tuesday, October, 31st. The biopharmaceutical company reported $0.91 earnings per share for the quarter, hitting the consensus estimate of $0.91. The biopharmaceutical company earned $919.03 million during the quarter, compared to analysts' expectations of $973.32 million. Incyte had a net margin of 11.78% and a trailing twelve-month return on equity of 11.21%.

ETFs with the largest weight of Incyte (NASDAQ:INCY) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), IQ U.S. Mid Cap R&D Leaders ETF (MRND), Virtus LifeSci Biotech Products ETF (BBP), First Trust Nasdaq Pharmaceuticals ETF (FTXH), ASYMshares ASYMmetric S&P 500 ETF (ASPY), American Century STOXX U.S. Quality Growth ETF (QGRO) and Strategas Global Policy Opportunities ETF (SAGP).

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Incyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Invesco Ltd. (1.75%), Acadian Asset Management LLC (1.20%), Northern Trust Corp (0.95%), Morgan Stanley (0.95%), Jacobs Levy Equity Management Inc. (0.93%) and Legal & General Group Plc (0.78%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends.

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.